Systemic Sclerosis Market Insight, Epidemiology And Market Forecast - 2036

Published Date : 2026
Pages : 206
Region : United States,

Systemic Sclerosis Market Summary

  • The Systemic Sclerosis Market is witnessing steady advancements, driven by increasing disease awareness, improvements in early diagnosis, and the development of novel targeted therapies aimed at managing disease progression, reducing complications, and improving patients' quality of life.
  • The leading Systemic Sclerosis Companies include Genentech, Kyowa Kirin, GSK, AstraZeneca, Amgen (Horizon Therapeutics), Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, aTyr Pharma, Kyorin Pharmaceutical, Cumberland Pharmaceuticals, and others.

Systemic Sclerosis Market & Epidemiology Insights

  • Systemic Sclerosis affects approximately 100,000 people in the United States, representing about one-third of individuals with Scleroderma. It is a chronic, multisystem disease requiring ongoing rheumatologic care, often with input from other medical specialties.
  • Systemic Sclerosis has a highly variable presentation, ranging from limited to diffuse disease with potentially severe lung, vascular, gastrointestinal, and renal complications; early symptoms such as Raynaud's phenomenon and puffy fingers may precede diagnosis. 
  • Systemic Sclerosis is associated with high autoantibody prevalence, with antinuclear antibodies present in ≥90% of cases and disease-specific anticentromere, anti-RNA polymerase III, and anti-Scl-70 antibodies in up to 70%; genetic and environmental factors may contribute to disease development. 
  • The disease predominantly affects females, with women accounting for ~80% of patients, while disease severity and organ involvement can vary according to sex, age, disease subtype, and autoantibody profile.
  • Diagnosis of Systemic Sclerosis requires a multidisciplinary assessment of clinical features, disease-specific autoantibodies, nailfold capillaroscopy, and internal-organ involvement, as early and heterogeneous presentations can lead to underdiagnosis and treatment delays. 
  • The current Systemic Sclerosis Treatment paradigm is organ- and disease-course-driven, combining immunomodulatory, antifibrotic, vasculopathy-directed, and supportive approaches. Nintedanib (OFEV) (FDA-approved 2019) and Tocilizumab (ACTEMRA) (FDA-approved 2021) slow pulmonary function decline in Systemic Sclerosis-associated interstitial lung disease, with tocilizumab being the first IL-6-targeted biologic approved for this indication; mycophenolate mofetil and rituximab are also used based on disease manifestations. 
  • The expiry of tocilizumab’s core patents has enabled the entry of tocilizumab biosimilars, while the closure of nintedanib’s primary exclusivity period is opening opportunities for generic nintedanib, shifting the market toward more cost-effective treatment options. 
  • The FDA has approved the first generic nintedanib applications from major manufacturers, including Cipla, Apotex, and Dr. Reddy’s, with price erosion expected to affect brand revenue over the next 24 months, while Boehringer Ingelheim continues efforts to protect its franchise.
  • The Systemic Sclerosis Pipeline is expanding toward targeted and potentially disease-modifying therapies, including AstraZeneca’s anifrolumab (SAPHNELO), GSK’s belimumab (BENLYSTA), aTyr Pharma’s efzofitimod, Boehringer Ingelheim’s nerandomilast and avenciguat, Mitsubishi Tanabe Pharma’s inebilizumab (UPLIZNA/MT-0551), and Galderma’s nemolizumab, targeting fibrosis, inflammation, and progressive organ involvement.

Request to unlock the Sample Page of the "Systemic Sclerosis Treatment Market"

Systemic Sclerosis Market

Systemic Sclerosis Market Size and Forecast in the 7MM

2025 Systemic Sclerosis Market Size~USD 1,900 million
2036 Projected Systemic Sclerosis Market Size~ USD XXX million
Systemic Sclerosis Growth Rate (2026–2036)~3% CAGR

Key Factors Driving the Growth of the Systemic Sclerosis Market

  • Increasing Recognition and Diagnosis of Systemic Sclerosis

Increasing awareness, autoantibody testing, nailfold capillaroscopy, and organ screening are enabling earlier Systemic Sclerosis diagnosis, while greater recognition of Systemic Sclerosis-associated interstitial lung disease is expanding the treated population and demand for disease-modifying therapies.

  • Rising Opportunities in Systemic Sclerosis Therapeutic Development

Persistent unmet needs in Fibrosis, Interstitial Lung Disease, Vascular Dysfunction, and multisystem involvement continue to drive innovation beyond nintedanib and tocilizumab, with emerging therapies targeting type I interferon, B cells, inflammation, fibrosis, and immune dysregulation.

  • Emerging Systemic Sclerosis Competitive Landscape

The Systemic Sclerosis pipeline is increasingly diversified, with anifrolumab, belimumab, guselkumab, avenciguat, nemolizumab, zola-cel, efzofitimod, nerandomilast, and inebilizumab/MT-0551 advancing alongside nintedanib and tocilizumab, spanning interferon, B-cell, cytokine, antifibrotic, and cellular therapies to address diverse disease manifestations and patient subgroups.

DelveInsight's ‘Systemic Sclerosis Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of Systemic Sclerosis, historical and forecasted epidemiology, as well as the Systemic Sclerosis market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Systemic Sclerosis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Systemic Sclerosis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in Systemic Sclerosis and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Scope of the Systemic Sclerosis Market Report

Study Period

2022–2036

Historical Year

2022–2025

Forecast Period

2026–2036

Base Year

2026

Geographies Covered

  • North America: The US;
  • Europe: Germany, France, Italy, Spain and the UK;
  • Asia-Pacific: Japan;

Systemic Sclerosis Market CAGR (Forecast period)

~3% (2026–2036)

Systemic Sclerosis Epidemiology Segmentation Analysis

Patient Burden Assessment

  • Total Systemic Sclerosis Diagnosed Prevalent Cases
  • Systemic Sclerosis Disease Subset-specific Diagnosed Prevalent Cases
  • Systemic Sclerosis Age-specific Diagnosed Prevalent Cases
  • Systemic Sclerosis Organ Involvement-specific Diagnosed Prevalent Cases
  • Systemic Sclerosis Severity by Organ Damage Diagnosed Prevalent Cases
  • Systemic Sclerosis Severity by Skin Thickness Diagnosed Prevalent Cases
  • Systemic Sclerosis Treated Cases

Systemic Sclerosis Companies

  • AstraZeneca
  • GSK
  • aTyr Pharma
  • Boehringer Ingelheim
  • Mitsubishi Tanabe Pharma
  • Zenyaku Kogyo
  • Chugai Pharmaceutical
  • Bristol Myers Squibb
  • Galderma
  • Amgen, and others

Systemic Sclerosis Therapies

  • Nintedanib (OFEV) 
  • Tocilizumab (ACTEMRA)
  • Anifrolumab (SAPHNELO) 
  • Belimumab (BENLYSTA) 
  • Avenciguat
  • Nemolizumab
  • Zolacabtagene- Autoleucel/​Zola-cel (BMS-986353)
  • Efzofitimod
  • Nerandomilast (BI 1015550)
  • Inebilizumab/MT-0551 (UPLIZNA), and others

Systemic Sclerosis Market

Segmented by

  • Region/Geographies
  • Drugs/Therapies

 

 

 

Analysis

  • Addressable Patient Population
  • Market Drivers and Market Barriers
  • Cost Assumptions and Pricing Analogues
  • KOL Views
  • SWOT Analysis
  • Reimbursement
  • Conjoint Analysis
  • Unmet Need

Systemic Sclerosis Understanding: Overview

Systemic Sclerosis is a chronic, multisystem autoimmune disorder characterized by immune dysregulation, small-vessel vasculopathy, and progressive fibrosis of the skin and internal organs.

The disease is clinically heterogeneous and broadly classified into limited cutaneous and diffuse cutaneous Systemic Sclerosis, with manifestations ranging from Raynaud phenomenon and skin thickening to severe interstitial lung disease, pulmonary arterial hypertension, gastrointestinal involvement, and scleroderma renal crisis. 

Disease development is associated with genetic susceptibility, environmental triggers, vascular injury, and dysregulated immune and fibrotic pathways. 

Systemic Sclerosis Diagnosis

The diagnosis of Systemic Sclerosis is based on a comprehensive clinical assessment supported by disease-specific autoantibody testing, nailfold capillaroscopy, and evaluation of internal-organ involvement, as no single diagnostic test definitively confirms the disease.

The 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria incorporate skin thickening, fingertip lesions, abnormal nailfold capillaries, pulmonary arterial hypertension or interstitial lung disease, Raynaud phenomenon, and Systemic Sclerosis-associated autoantibodies.

Anticentromere, anti-topoisomerase I, and anti-RNA polymerase III antibodies provide important diagnostic and prognostic information, while pulmonary function testing, high-resolution computed tomography, echocardiography, and other organ assessments help identify clinically significant internal-organ involvement.

Further details are provided in the report.

Current Systemic Sclerosis Treatment Landscape

The treatment of Systemic Sclerosis is primarily organ- and manifestation-directed and aims to control immune-mediated inflammation, slow fibrosis, preserve organ function, and prevent disease-related complications. Standard management includes immunomodulatory therapies, antifibrotic treatment such as nintedanib, tocilizumab for selected patients with interstitial lung disease, and supportive treatment for manifestations such as Raynaud phenomenon, digital ulcers, pulmonary arterial hypertension, gastrointestinal involvement, and renal complications.

Regular multidisciplinary monitoring is essential to identify progressive interstitial lung disease, pulmonary hypertension, skin fibrosis, and other internal-organ involvement and to guide treatment escalation.

Further details related to country-based variations are provided in the report.

Systemic Sclerosis Unmet Needs

The section “unmet needs of Systemic Sclerosis” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

  1. Limited disease-modifying treatment options across disease manifestations
  2. Challenges in demonstrating disease-modifying effects
  3. Difficulty in early recognition and diagnosis
  4. Heterogeneous disease presentation and variable treatment response
  5. Limited availability of precision and subtype-specific therapies, and others….

Note:  Comprehensive unmet needs insights in Systemic Sclerosis and their strategic implications are provided in the full report.

Systemic Sclerosis Epidemiology Insights in the 7MM

Key Findings from Systemic Sclerosis Epidemiological Analysis and Forecast

  • As per DelveInsight's analyst, the diagnosed prevalent cases of Systemic Sclerosis in the 7MM were estimated to be ~ 232,400 cases in 2025.
  • Among EU4 and the UK, Italy had the highest number (~8%) of diagnosed prevalent cases of Systemic Sclerosis, while Spain had the lowest number of diagnosed prevalent cases.
  • Among the age-specific cases, 40–69 age group (~60%) had the highest prevalent cases in the US followed by 70 and above in 2025.
  • In the US, mild organ damage cases of Systemic Sclerosis was found to be more as compared to moderate and severe organ damage cases in 2025.
  • According to DelveInsight estimates, the majority of Systemic Sclerosis cases in the US are classified as limited cutaneous Systemic Sclerosis, accounting for approximately 65% of the total cases in 2025, making it the most prevalent subtype compared to diffuse cutaneous Systemic Sclerosis and Systemic Sclerosis sine scleroderma.
  • In EU4 and the UK had nearly 81,000 cases of Systemic Sclerosis in 2025.
  • The prevalence of Systemic Sclerosis is estimated at approximately 10–30 cases per 100,000 individuals worldwide, although reported estimates vary substantially across countries because of differences in diagnostic criteria, case ascertainment, and healthcare access.

Systemic Sclerosis Epidemiology Segmentation in the 7MM

  • Total Systemic Sclerosis Diagnosed Prevalent Cases
  • Systemic Sclerosis Disease Subset-specific Diagnosed Prevalent Cases
  • Systemic Sclerosis Age-specific Diagnosed Prevalent Cases
  • Systemic Sclerosis Organ Involvement-specific Diagnosed Prevalent Cases
  • Systemic Sclerosis Severity by Organ Damage Diagnosed Prevalent Cases
  • Systemic Sclerosis Severity by Skin Thickness Diagnosed Prevalent Cases
  • Systemic Sclerosis Treated Cases

Systemic Sclerosis Market Recent Breakthroughs and Developments

  • On November 09, 2026 – Nkarta announced initial clinical results for NKX019, an investigational allogeneic CAR NK-cell therapy, in systemic sclerosis at ACR Convergence 2026. Among patients receiving the 4-billion-cell dose, 6 of 7 (86%) achieved an rCRISS-25 response or greater, while 5 of 7 (71%) achieved an rCRISS-50 response or greater. The treatment also demonstrated improvements in skin symptoms, including a median 15-point reduction in modified Rodnan skin score at Day 90.
  • On November 09, 2026, Allogene Therapeutics announced preliminary Phase I RESOLUTION study results for ALLO-329, an investigational allogeneic CAR-T therapy being evaluated for autoimmune diseases, including systemic sclerosis. Eight of 10 systemic sclerosis patients achieved and maintained clinically meaningful improvements in modified Rodnan skin scores, while nine of 10 remained off background immunosuppressive therapy. The findings highlight the potential of CAR-T-based approaches in treating systemic sclerosis.
  • On November 09, 2026 – Aisa Pharma announced additional Phase II RECONNOITER-1 trial data for AISA-021 (cilnidipine), targeting systemic sclerosis-associated Raynaud's phenomenon. The treatment significantly reduced the median weekly frequency and duration of Raynaud's attacks while increasing attack-free days. The company is preparing to initiate a global Phase III pivotal study and has requested an FDA Type C meeting to discuss its development and regulatory strategy.
  • On November 08, 2026 – CRISPR Therapeutics reported encouraging Phase I clinical data for zugocabtagene geleucel (zugo-cel), an investigational gene-edited allogeneic CAR-T therapy targeting CD19 in refractory autoimmune diseases, including systemic sclerosis. Among patients with systemic sclerosis receiving standard lymphodepletion, 83% (5/6) achieved a clinical response at Month 3, with all five responders maintaining their responses. The therapy was well tolerated, with no reported cytokine release syndrome above Grade 2.
  • In August 2026, aTyr Pharma announced that enrollment had been completed in the Phase II EFZO-CONNECT study evaluating efzofitimod in patients with limited or diffuse Systemic Sclerosis-associated interstitial lung disease. Topline results are expected in the first quarter of 2027, supporting continued development of efzofitimod as a potential disease-modifying therapy for Systemic Sclerosis-ILD.
  • H1 data readout is anticipated for SAPHNELO in 2027.
  • In July 2026, Galderma initiated the Phase II study of nemolizumab in adults with Systemic Sclerosis. The randomized study is evaluating the effect of nemolizumab on cutaneous thickness at Week 52, with a planned 154 participants and a 156-week extension to assess longer-term safety and efficacy.
  • In July 2026, Boehringer Ingelheim initiated a Phase III study of nerandomilast (BI 1015550) in adults with Systemic Sclerosis. The randomized, placebo-controlled study is evaluating whether oral nerandomilast can improve disease outcomes and slow progression, with assessments including skin thickening, lung function, and internal-organ involvement.

Systemic Sclerosis Drug Analysis & Competitive Landscape

The Systemic Sclerosis drug chapter provides a detailed, market-focused review of the emerging Systemic Sclerosis Pipeline across Phase III clinical trials and preclinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Systemic Sclerosis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Systemic Sclerosis therapeutics market.

Systemic Sclerosis Approved Therapies

  • Nintedanib (OFEV): Boehringer Ingelheim

Nintedanib (OFEV) is in a class of medications called kinase inhibitors and works by blocking the action of enzymes involved in causing fibrosis. In 2016, nintedanib was granted Orphan Drug Designation (ODD) by the US FDA for the treatment of Systemic Sclerosis-ILD and by the European Commission (EC) for the treatment of SSc.

In September 2019, the US FDA approved nintedanib for the treatment of SSc-ILD. In June 2025, Boehringer Ingelheim announced that The EC approved nintedanib in adolescents and children aged 6 years and older for the treatment of SSc-ILD. The approval was based on the InPedILD Phase III clinical trial.

 The core composition patent for nintedanib officially expired in April 2026. This has triggered immediate disruption in a market where nintedanib was generating roughly USD 3.76 billion to USDv3.8 billion annually in sales.

  • Rituximab (RITUXAN): Zenyaku Kogyo/Chugai Pharmaceutical 

Rituximab (RITUXAN) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells other than stem cells and plasma cells. It attacks target B cells along with the body’s immune system equipped the human body, and damages cells. In September 2021, Zenyaku obtained approval from the Ministry of Health, Labour and Welfare for an anti-CD20 monoclonal antibody, rituximab injection of 100 mg and 500 mg for an additional indication of Systemic Sclerosis. 

In the US and Europe, physicians frequently use rituximab off-label to manage severe Systemic Sclerosis symptoms

 Note: Detailed marketed therapies assessment will be provided in the final report

Systemic Sclerosis Marketed/Approved Therapies

Product

Company

MoA

Indication

RoA

Molecule

Type

Initial Approval

Nintedanib (OFEV)

Boehringer Ingelheim

Multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine

kinases (nRTKs)

Systemic Sclerosis- ILD

Oral

Small molecule

US: 2019

EU: 2020

JP: 2019

Rituximab (RITUXAN)

Zenyaku Kogyo/Chugai Pharmaceutical

Anti-CD20

Systemic Sclerosis

IV infusion

Monoclonal antibody

JP: 2021

Systemic Sclerosis Pipeline Analysis

  • Belimumab (BENLYSTA): GSK 

Belimumab is a B-lymphocyte stimulator (BLyS) specific inhibitor that binds to soluble BLyS, which is found to be increased in patients with systemic autoimmune diseases. Currently, it is being studied in Phase II/III for SSc-ILD. In February 2023, the US FDA granted ODD to belimumab for the potential treatment of Systemic Sclerosis.

  • Anifrolumab (SAPHNELO) : AstraZeneca

Anifrolumab is a first-in-class, fully human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1). Currently, the drug is being evaluated a Phase III DAISY study in adult participants with Systemic Sclerosis. In October 2013, anifrolumab was granted ODD by the US FDA for the treatment of Systemic Sclerosis.

  • Nemolizumab: Galderma

Nemolizumab is a monoclonal antibody that targets IL-31 receptor alpha, a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in the two diseases. The company is continuously exploring its potential to treat a wider range of patients and conditions, including Systemic Sclerosis and Chronic Pruritus of Unknown Origin (CPUO).

In June 2025, Galderma announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with SSc and CPUO – two chronic conditions with high unmet need. Both conditions are associated with poor patient outcomes and low quality of life, and can be life-threatening.

Competitive Landscape of Systemic Sclerosis Pipeline Therapies

Drug Name

Company

Highest Phase

Indication

RoA

MoA

Anticipated Launch in the US

Belimumab (BENLYSTA)

GSK

III

Systemic Sclerosis-associated interstitial lung disease

SC

Anti-B lymphocyte stimulator

Information is available in the full report

Anifrolumab (SAPHNELO)

AstraZeneca

III

Limited or diffuse cutaneous Systemic Sclerosis

Subcutaneous

Type I interferon receptor antagonist

Information is available in the full report

Efzofitimod

aTyr Pharma

II

Systemic Sclerosis-related interstitial lung disease

IV infusion

NRP2 modulator

Information is available in the full report

Note: Launch insights are provisional and may change with future report updates or the occurrence of major key catalysts.

Note: Detailed emerging therapies assessment will be provided in the final report.

Systemic Sclerosis Market Outlook

The current treatment landscape for Systemic Sclerosis remains largely organ- and manifestation-directed, focusing on immunosuppression, antifibrotic treatment, vascular management, and prevention of progressive organ damage. Standard management includes methotrexate, mycophenolate mofetil, azathioprine, cyclophosphamide, glucocorticoids, vasoactive therapies, and supportive treatment according to disease manifestations.

Nintedanib (OFEV) was approved by the US FDA in September 2019 to slow the rate of decline in pulmonary function in patients with Systemic Sclerosis-associated interstitial lung disease, followed by Tocilizumab (ACTEMRA) in March 2021 for the same pulmonary indication.

Rituximab (RITUXAN) also provides a Systemic Sclerosis-specific treatment option in Japan, while substantial unmet need remains across skin fibrosis, progressive interstitial lung disease, vascular complications, and multisystem disease.

Future sales growth is expected to increasingly depend on pipeline differentiation and expansion into broader disease manifestations, as current products address specific organ involvement rather than the full Systemic Sclerosis disease spectrum.

The entry of zola-cel, anifrolumab, nerandomilast, efzofitimod, and inebilizumab could expand the addressable market, while continued attrition of programs such as Lenabasum, HZN-825, and BI 685509 highlights the clinical-development risk that could limit future market expansion.

Overall, the Systemic Sclerosis Therapeutics Market across the 7MM is expected to witness steady growth through 2036, driven by increasing recognition of internal-organ involvement, greater screening for Systemic Sclerosis-associated interstitial lung disease, continued use of established antifibrotic and immunomodulatory therapies, and the potential introduction of targeted therapies with broader disease-modifying effects.

The expanding Systemic Sclerosis Pipeline is particularly important given that existing therapies predominantly slow disease progression or address individual manifestations rather than reverse established fibrosis. Successful development of therapies that provide durable control of skin fibrosis, pulmonary disease, vascular dysfunction, and systemic inflammation could progressively shift the market toward earlier, targeted, and more comprehensive disease modification.

Key findings from the Systemic Sclerosis Market Forecast

  • Nintedanib and tocilizumab currently anchor the US disease-specific treatment landscape for SS-ILD, while rituximab provides an additional approved option in Japan. 
  • The emerging Systemic Sclerosis Pipeline is moving beyond organ-specific management, with programs such as zola-cel, nerandomilast, efzofitimod, anifrolumab, and inebilizumab evaluating approaches that could address broader immune, fibrotic, or vascular drivers of Systemic Sclerosis.

Further details will be provided in the report….

Systemic Sclerosis Companies

  • AstraZeneca
  • GSK
  • aTyr Pharma
  • Boehringer Ingelheim
  • Mitsubishi Tanabe Pharma
  • Zenyaku Kogyo
  • Chugai Pharmaceutical
  • Bristol Myers Squibb
  • Galderma
  • Amgen

Systemic Sclerosis Drug Class/Insights into Leading Emerging and Marketed Therapies (2022–2036 Forecast)

The Systemic Sclerosis Therapeutics Market (2022–2036 forecast) is gradually evolving from manifestation-specific management toward targeted therapies addressing the underlying Immune Dysregulation, Vascular Dysfunction, and Progressive Fibrosis associated with disease progression. Current Systemic Sclerosis Treatment remains largely focused on slowing organ damage and controlling individual manifestations, while emerging therapeutic approaches are increasingly designed to provide broader and potentially disease-modifying effects across skin, pulmonary, vascular, and systemic involvement.

  • Receptor Tyrosine Kinase Inhibition: Nintedanib inhibits PDGFR, FGFR, and VEGF, reducing signaling involved in fibroblast activation, proliferation, and extracellular matrix production. This mechanism primarily aims to slow progressive fibrotic remodeling, particularly in Systemic Sclerosis-associated interstitial lung disease. 
  • Type I Interferon Receptor Blockade: Anifrolumab targets IFNAR1, the common receptor subunit for type I interferons, thereby inhibiting downstream interferon signaling. This approach is intended to reduce interferon-driven immune activation that has been implicated in Systemic Sclerosis inflammation and tissue fibrosis. 
  • NRP2-Targeted Immunomodulation: Efzofitimod targets neuropilin-2 (NRP2) and is designed to modulate inflammatory and fibrotic pathways involved in tissue injury. Its mechanism is being investigated particularly in Systemic Sclerosis-associated interstitial lung disease, where reducing both inflammation and fibrosis could address disease progression.
  • IL-31 Receptor A Blockade: Nemolizumab blocks IL-31 receptor A (IL-31RA), inhibiting IL-31 signaling. This mechanism may reduce IL-31-mediated inflammatory and pruritic signaling and is being investigated as a targeted approach for Systemic Sclerosis manifestations. 

Systemic Sclerosis Drug Uptake

This section focuses on the uptake rate of potential Systemic Sclerosis Therapies expected to be launched in the market during the forecast period (2026–2036). The analysis covers the Systemic Sclerosis therapies' uptake, performance at peak, factors influencing commercial adoption during the growth phase, patient uptake by therapy, and anticipated sales generated by each therapy.

Current treatment uptake in Systemic Sclerosis is primarily driven by immunosuppressive and antifibrotic therapies, with treatment selection varying by disease subtype, organ involvement, and severity.

Mycophenolate mofetil, methotrexate, cyclophosphamide, rituximab, and nintedanib are used across relevant manifestations, while organ-specific therapies remain important. Uptake of newer targeted treatments is expected to increase as evidence and clinical experience develop.

Emerging targeted immunomodulatory, antifibrotic, and cellular therapies are expected to gain uptake based on efficacy, organ-specific benefits, safety, convenience, and differentiation from existing treatments. Adoption is likely to be gradual due to disease heterogeneity, varied organ involvement, patient selection, and established treatment practices, while improved diagnosis, stratification, and clinical experience are expected to support market growth through 2036.

Detailed insights of emerging therapies' drug uptake is included in the report

Systemic Sclerosis Market Access and Reimbursement of Approved Therapies

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The United States

US Reimbursement of Therapies Approved for Systemic Sclerosis

Drug/Therapy

Access Program

nintedanib (OFEV)

The OFEV Commercial Copay Program

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

NOTE: Further Details are provided in the final report….

Systemic Sclerosis Therapies Price Scenario & Trends 

Pricing and analogue assessment of systemic scelrosis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

  • Pricing of Systemic Sclerosis approved drugs

The wholesale acquisition price (WAC) for nintedanib (OFEV) is USD 9,600 for a package containing 60 capsules, translating to a unit cost of USD 160. This results in an annual cost of USD 115,200.

Industry Experts and Physician Views for Systemic Sclerosis

To keep up with Systemic Sclerosis Therapeutics Market Trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. 

Industry experts were contacted for insights on Systemic Sclerosis Emerging Therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Systemic Sclerosis, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights at the country level. Centers such as Descartes University, University of Wisconsin, School of Medicine, University of Leicester, and University of Texas McGovern Medical School, etc. were contacted.

Their opinions help understand and validate current and emerging Systemic Sclerosis therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Systemic Sclerosis.

Region

Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs)

United States

“Systemic Sclerosis and pulmonary fibrosis have profound consequences on patients’ and caregivers’ health-related quality of life, working ability, psychological wellbeing and social interactions. Some activities may help patients and families deal with these aspects of the disease.”

France

“The safety profile of nintedanib over 148 weeks of SENSCIS-ON was consistent with that reported in the SENSCIS trial, characterized mainly by gastrointestinal events that were manageable for most patients. These results support the potential use of nintedanib in the long-term treatment of patients with Systemic Sclerosis-ILD”

Systemic Sclerosis Report Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and Systemic Sclerosis Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis of Systemic Sclerosis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

  • The report covers a segment of key events, an executive summary, a descriptive overview of Systemic Sclerosis, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
  • Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
  • A detailed review of the Systemic Sclerosis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Systemic Sclerosis market.

Report Insights

  • Systemic Sclerosis Patient Population Forecast
  • Systemic Sclerosis Therapeutics Market Size
  • Systemic Sclerosis Pipeline Analysis
  • Systemic Sclerosis Market Size and Trends
  • Systemic Sclerosis Market Opportunity (Current and forecasted)

 

Report Key Strengths

  • Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
  • Artificial Intelligence (AI)-Enabled Market Research Report
  • 11-Year Forecast
  • Systemic Sclerosis Market Outlook (North America, Europe, Asia-Pacific)
  • Patient Burden Trends (By Geography)
  • Systemic Sclerosis Treatment Addressable Market (TAM)
  • Systemic Sclerosis Competitve Landscape
  • Systemic Sclerosis Major Companies Insights
  • Systemic Sclerosis Price Trends and Analogue Assessment
  • Systemic Sclerosis Therapies Drug Adoption/Uptake
  • Systemic SclerosisTherapies Peak Patient Share Analysis

Report Assessment

  • Systemic Sclerosis Current Treatment Practices
  • Systemic Sclerosis Unmet Needs
  • Systemic Sclerosis Clinical Development Analysis
  • Systemic Sclerosis Emerging Drugs Product Profiles
  • Systemic Sclerosis Market attractiveness
  • Systemic Sclerosis Qualitative Analysis (SWOT and conjoint analysis)

FAQs

Market Insights

  • What was the Systemic Sclerosis market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
  • What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
  • What can be the future treatment paradigm of Systemic Sclerosis?
  • What are the disease risks, burdens, and unmet needs of Systemic Sclerosis? What will be the growth opportunities across the 7MM concerning the patient population with Systemic Sclerosis?
  • Who is the major future competitor in the market, and how will the competitors affect their market share?
  • What are the current options for the treatment of Systemic Sclerosis? What are the current guidelines for treating Systemic Sclerosis in the US, Europe, and Japan?

Reasons to Buy

  • The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Systemic Sclerosis market.
  • Bottom‑up forecasting builds from the affected population to product forecasts, delivering a robust, data‑driven approach ideal for new therapies and novel classes.
  • Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
  • Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
  • Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
  • To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
  • Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
  • This Artificial Intelligence (AI)‑enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data‑driven decisions.

Frequently Asked Questions

Systemic Sclerosis (SSc), also known as scleroderma, is a rare autoimmune disease characterized by hardening and tightening of the skin and connective tissues. It can also affect internal organs such as the lungs, heart, kidneys, and digestive tract. Symptoms include skin thickening, Raynaud’s phenomenon (cold fingers/toes), joint pain, fatigue, and organ dysfunction. The exact cause is unknown, but it involves immune system dysregulation, vascular abnormalities, and excessive collagen production.
The Systemic Sclerosis Therapeutics Market Size was valued at ~USD 1,900 Million in 2025 and is expected to grow at a notable CAGR over the study period (2022–2036).
In 2023, the United States held the largest share of the Systemic Sclerosis market size within the 7MM, valued at approximately USD 1,380 million.
The leading Systemic Sclerosis Companies include Kyowa Kirin, GSK, AstraZeneca, Amgen (Horizon Therapeutics), Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, aTyr Pharma, Kyorin Pharmaceutical, Cumberland Pharmaceuticals, and others.
Key strengths of the Systemic Sclerosis Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Systemic Sclerosis Market.
The United States is expected to have the highest prevalence of Systemic Sclerosis cases among the studied regions.
The epidemiology section of the Systemic Sclerosis report presents both historical and forecasted data, segmented by total diagnosed prevalent cases, cases by disease subset, age-specific cases, cases with organ involvement, severity by organ damage, and severity by skin thickness across the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan for the period 2022–2036

Tags:

  • Systemic Sclerosis market
  • Systemic Sclerosis market research
  • Systemic Sclerosis market insight
  • Systemic Sclerosis market trends

Related Reports

report image delveinsight

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Market Insight, Epidemiology and Market Forecast - 2028

report image delveinsight

Diffuse cutaneous systemic sclerosis (dcSSc) Market Insight, Epidemiology And Market Forecast - 2034

report image delveinsight

Systemic Sclerosis-associated Interstitial Lung Disease Market Insight, Epidemiology And Market Forecast - 2034

report image delveinsight

Diffuse cutaneous systemic sclerosis (dcSSc) - Pipeline Insight, 2026

Infographics

License Type


Offer

Request Sample

View Pricing

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

Have a Question?

We are happy to assist you.

Download Now

Infographic Image
DelveInsight
DelveInsight
SUBSCRIPTION
Platform

Register for free trial today and gain instant access to 7000+ market
research reports